Disclosed are compounds of the formula (I)
wherein the groups R
1
to R
3
have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS
申请人:Boehringer Ingelheim International GmbH
公开号:US20160129001A1
公开(公告)日:2016-05-12
Method for treating AML and MM by administration of a compound of the formula (I)
wherein the groups R
1
to R
3
have the meanings given in the specification.
TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
申请人:Boehringer Ingelheim International GmbH
公开号:EP2925761B1
公开(公告)日:2017-07-05
[EN] TRIAZOLOPYRAZINE<br/>[FR] TRIAZOLOPYRAZINE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2014076237A1
公开(公告)日:2014-05-22
The present invention encompasses compounds of general formula (I) wherein the groups R1 to R 3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.